Shares of Synthetic Biologics Inc (NYSEMKT:SYN) have earned a consensus recommendation of “Hold” from the eight research firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $5.45.

SYN has been the subject of a number of research analyst reports. Zacks Investment Research downgraded shares of Synthetic Biologics from a “buy” rating to a “hold” rating in a report on Friday, April 7th. William Blair reiterated an “outperform” rating and issued a $5.00 price target on shares of Synthetic Biologics in a report on Monday, May 22nd. Finally, ValuEngine downgraded shares of Synthetic Biologics from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd.

Institutional investors have recently bought and sold shares of the stock. Norges Bank acquired a new position in Synthetic Biologics during the fourth quarter valued at $356,000. LMR Partners LLP acquired a new position in Synthetic Biologics during the second quarter valued at $194,000. Bank of New York Mellon Corp increased its position in Synthetic Biologics by 3.1% in the first quarter. Bank of New York Mellon Corp now owns 263,598 shares of the company’s stock valued at $166,000 after buying an additional 7,962 shares during the period. UBS Group AG increased its position in Synthetic Biologics by 10.3% in the first quarter. UBS Group AG now owns 214,357 shares of the company’s stock valued at $135,000 after buying an additional 20,038 shares during the period. Finally, Creative Planning increased its position in Synthetic Biologics by 65.4% in the second quarter. Creative Planning now owns 177,000 shares of the company’s stock valued at $100,000 after buying an additional 70,000 shares during the period.

Shares of Synthetic Biologics (SYN) traded up 15.000% during mid-day trading on Friday, hitting $0.598. 3,174,673 shares of the stock traded hands. Synthetic Biologics has a 12-month low of $0.41 and a 12-month high of $1.90. The firm’s market cap is $72.89 million. The firm’s 50 day moving average price is $0.57 and its 200 day moving average price is $0.64.

Synthetic Biologics (NYSEMKT:SYN) last announced its quarterly earnings data on Thursday, August 3rd. The company reported ($0.03) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.06) by $0.03. On average, equities research analysts predict that Synthetic Biologics will post ($0.21) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/08/04/analysts-set-synthetic-biologics-inc-syn-pt-at-5-45.html.

About Synthetic Biologics

Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.

Analyst Recommendations for Synthetic Biologics (NYSEMKT:SYN)

Receive News & Stock Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related stocks with our FREE daily email newsletter.